A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization**Presented in part at the 46th Annual Meeting of the American Fertility Society, Washington, D.C., October 15 to 18, 1990.

1992 ◽  
Vol 58 (4) ◽  
pp. 744-749 ◽  
Author(s):  
Gabriel A. San Roman ◽  
Eric S. Surrey ◽  
Howard L. Judd ◽  
John F. Kerin
Keyword(s):  
In Vitro Fertilization ◽  
Annual Meeting ◽  
Luteal Phase ◽  
Follicular Phase ◽  
Gonadotropin Releasing Hormone ◽  
Vitro Fertilization ◽  
Phase Versus ◽  
Gonadotropin Releasing Hormone Agonist ◽  
American Fertility Society

scholarly journals Multiple-dose versus single-dose gonadotropin-releasing hormone agonist after first in vitro fertilization failure associated with luteal phase deficiency: A randomized controlled trial

2020 ◽  
Vol 48 (6) ◽  
pp. 030006052092602 ◽  
Author(s):  
Danni Qu ◽  
Yuan Li
Keyword(s):  
Single Dose ◽  
In Vitro Fertilization ◽  
Luteal Phase ◽  
Multiple Dose ◽  
Dose Group ◽  
Gonadotropin Releasing Hormone ◽  
Vitro Fertilization ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Ivf Failure

Objective To evaluate the efficacy and safety of multiple- versus single-dose gonadotropin-releasing hormone agonist (GnRH-a) addition to luteal phase support (LPS), in patients with a first in vitro fertilization (IVF) failure associated with luteal phase deficiency (LPD). Methods Eighty patients with a first IVF failure associated with LPD were randomly assigned into single-dose and multiple-dose GnRH-a groups. In the second IVF attempt, patients in the single-dose group were given standard LPS plus a single dose of GnRH-a 6 days after oocyte retrieval. Patients in the multiple-dose group received standard LPS plus 14 daily injections of GnRH-a. Children conceived were followed up for 2 years. Results Pregnancy (67.5% vs. 42.5%), clinical pregnancy (50.0% vs. 22.5%), and live birth rates (42.5% vs. 20.0%) were significantly higher in the multiple-dose versus single-dose GnRH-a group. Patients in the multiple-dose GnRH-a group had significantly higher progesterone levels 14 days after oocyte recovery (35.9 vs. 21.4 ng/mL). No significant difference existed in the status at birth or developmental and behavior assessments of 2-year-old children conceived in both groups. Conclusions Daily addition of GnRH-a to standard LPS can achieve better pregnancy outcomes with a sustained safety profile in patients with a first IVF failure associated with LPD.

Sign in / Sign up

Export Citation Format

Share Document